May 12, 2020 / 12:53 PM / 15 days ago

BRIEF-Moderna Receives FDA Fast Track Designation For Mrna Vaccine (Mrna-1273) Against Novel Coronavirus

May 12 (Reuters) - Moderna Inc:

* MODERNA RECEIVES FDA FAST TRACK DESIGNATION FOR MRNA VACCINE (MRNA-1273) AGAINST NOVEL CORONAVIRUS

* MODERNA INC - FINALIZING PROTOCOL FOR PHASE 3 STUDY OF MRNA-1273, EXPECTED TO BEGIN IN EARLY SUMMER OF 2020

* MODERNA INC - FINALIZING PROTOCOL FOR PHASE 3 STUDY OF MRNA-1273, EXPECTED TO BEGIN IN EARLY SUMMER OF 2020

* MODERNA INC - ACTIVELY PREPARING FOR PHASE 2, PHASE 3 CLINICAL STUDIES TO CONTINUE LEARNING ABOUT POTENTIAL OF MRNA-1273 TO PROTECT AGAINST SARS-COV-2

* MODERNA INC - FDA COMPLETED REVIEW OF IND APPLICATION FOR MRNA-1273; PHASE 2 STUDY EXPECTED TO BEGIN SHORTLY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below